NSCLC, Stage III Clinical Trials

28 clinical trials for NSCLC, Stage III across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC — RECRUITING · PHASE2
• Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC — RECRUITING · PHASE3
• Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study — RECRUITING · NA
• A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer — RECRUITING · NA
• Lung Cancer Registry — RECRUITING
• A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced — RECRUITING
• Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients — RECRUITING
• Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer — RECRUITING · PHASE2
• Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial — NOT_YET_RECRUITING · PHASE2
• Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer — NOT_YET_RECRUITING · PHASE2
• Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy — COMPLETED · PHASE2
• Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC — NOT_YET_RECRUITING · PHASE2
• A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC — COMPLETED · PHASE2
• A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China — COMPLETED
• Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer — WITHDRAWN · PHASE2
• Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab — WITHDRAWN · PHASE2
• Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study — ACTIVE_NOT_RECRUITING · PHASE2
• Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC — OTHER · PHASE2
• Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities — OTHER · PHASE2
• Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. — OTHER · PHASE2
• Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. — OTHER · PHASE2
• Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab — OTHER
• SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC — OTHER · PHASE2
• Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC — OTHER · PHASE2
• To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC — WITHDRAWN · NA
• The Role of Microbiota on the Development of Lung Cancer — OTHER

Refine this search